In any case, it appears from our experiments that dasatinib at therapeutic concentrations does not enhance CML cell binding to fibronectin (Figures 2 E,F and 3). The gene discussed is FN1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.